The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations

The third-generation EGFR inhibitor, osimertinib (AZD9291), selectively and irreversibly inhibits EGFR activating and T790 M mutants while sparing wild-type EGFR. Osimertinib is now an approved drug for non-small cell lung cancer (NSCLC) patients with activating EGFR mutations (first-line) or those...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Puyu, Zhang, Shuo, Zhu, Lei, Qian, Guoqing, Ren, Hui, Ramalingam, Suresh S., Chen, Mingwei, Sun, Shi-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411612/
https://www.ncbi.nlm.nih.gov/pubmed/30856555
http://dx.doi.org/10.1016/j.tranon.2019.02.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411612/
https://www.ncbi.nlm.nih.gov/pubmed/30856555
http://dx.doi.org/10.1016/j.tranon.2019.02.006

Ejemplares similares